Skip to content

D&A at other companies

Boston Scientific logo
Boston ScientificBSX
$351M+8.0%
Medtronic logo
MedtronicMDT
$716M-14.8%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$60K+22.4%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$5.11M+67.9%
LivaNova logo
LivaNovaLIVN
$8.3M+29.3%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$30.5M+4.1%

Other financials

Income statement

See full
Revenue$14.8M+19.6%
Gross profit$12.9M+24.9%
Operating income-$12.2M+9.5%
Net income-$13.1M+4.7%
EPS (diluted)-$0.50+5.7%

Balance sheet

See full
Cash & equivalents$72.3M-29.6%
Total debt$59.4M+17.8%
Total equity$29.1M-58.0%
Total assets$99.7M-23.0%

Cash flow

See full
Operating cash flow-$12.2M+4.7%
CapEx$122.0K+7.0%
Free cash flow-$12.3M+4.6%

Valuation

See full
Market cap$148.6M-2.9%
Enterprise value$135.69M+25.0%
P/S2.5×-0.3×

Profitability

See full
Gross margin86.2%+2.7pp
Operating margin-84.6%-8.9pp
Net margin-89.1%-7.0pp
FCF margin-68%-8.1pp

Returns & leverage

See full
Return on equity-107%+73.4pp
Debt / equity+1.3×
Current ratio10.2×-4.6×

Where this comes from

Reported directly by CVRx, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: CVRx, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about CVRx, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CVRx, Inc.'s D&A?
CVRx, Inc. (CVRX) reported D&A of $205K in Q1 2026.
How has CVRx, Inc.'s D&A changed year-over-year?
CVRx, Inc.'s D&A increased by 11.4% year-over-year, from $184K to $205K.
What is the long-term trend for CVRx, Inc.'s D&A?
Over 4 years (2021 to 2025), CVRx, Inc.'s D&A has grown at a 45.6% compound annual growth rate (CAGR), from $168K to $756K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.